Bg Medicine, Inc. (BGMD)
OTC PINK OTC PINK Primary Summary
Bg Medicine, Inc. (BGMD) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Bg Medicine, Inc. ever had a stock split?
Bg Medicine, Inc. Profile
| Electronic Equipment, Instruments & Components Industry | Information Technology Sector | Stephen Hall CEO | OTC PINK Exchange | 08861T206 CUSIP |
| US Country | 5 Employees | - Last Dividend | 9 Jul 2015 Last Split | - IPO Date |
Overview
BG Medicine, Inc., originally founded as Beyond Genomics, Inc., underwent a name change in October 2004 to better reflect its evolved focus and mission. With its inception in 2000, this pioneering entity set up its headquarters in Waltham, Massachusetts, marking a noteworthy journey in the biotechnology domain. The company dedicates itself to the advancement and commercialization of distinctive diagnostic solutions primarily aimed at managing heart failure and associated disorders. Catering to the United States market, BG Medicine, Inc. has established productive partnerships through license, development, and commercialization agreements with esteemed organizations like Abbott Laboratories, bioMérieux SA, Siemens Healthcare Diagnostics Inc., and Alere Inc. Notably, the company has entered into a strategic collaboration with Abbott Laboratories for the purpose of developing and commercializing galectin-3 assay kits, which includes control kits and calibrators, representing a significant stride towards the realization of their innovative diagnostic products.
Products and Services
- BGM Galectin-3 Test
- CardioSCORE Test
An innovative in vitro diagnostic tool designed to measure galectin-3 levels in serum or plasma. This test, which utilizes enzyme-linked immunosorbent assay (ELISA) technology on a microtiter plate platform, serves as a critical resource in diagnosing and managing heart failure and related disorders. Through its precise measurement capabilities, healthcare professionals can gain valuable insights into a patient's condition, enabling informed clinical decisions and targeted treatment strategies.
This multi-analyte biomarker-based blood test stands as a testament to BG Medicine, Inc.'s commitment to cardiovascular health. Aimed at assessing the near-term risk of atherothrombotic cardiovascular events, such as heart attacks and ischemic strokes, the CardioSCORE Test represents a significant advancement in preventive healthcare. By evaluating a panel of biomarkers, it provides a comprehensive risk profile that can guide patients and healthcare providers in preempting potential cardiovascular issues through early intervention and personalized care plans.
